Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST).

Trial Profile

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms CONVERT
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 01 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top